Table 3.
Treatment-related adverse events due to the chemotherapy regimen, n (%)
| FOLFIRINOX (n = 86) | Gem + nabPTX (n = 81) | P value | |
| Hematologic adverse event | |||
| Grade ≥ 3 Anemia | 17 (19.8) | 12 (14.8) | 0.398 |
| Grade ≥ 3 Thrombocytopenia | 7 (8.1) | 5 (6.2) | 0.623 |
| Grade ≥ 3 Neutropenia | 64 (74.4) | 38 (46.9) | < 0.001 |
| Febrile neutropenia | 22 (25.6) | 13 (16.0) | 0.130 |
| Administration of G-CSF | 66 (76.7) | 15 (18.5) | < 0.001 |
| Neurologic adverse event | |||
| Peripheral neuropathy | 16 (18.6) | 46 (56.8) | < 0.001 |
| Grade ≥ 3 neuropathy | 3 (3.5) | 15 (18.5) | 0.002 |
| Median time to onset-days (range) | 120 (15-278) | 73.5 (17-284) | 0.051 |
| Gastrointestinal adverse event | |||
| Nausea/Vomiting | 43 (50.0) | 17 (21.0) | < 0.001 |
| Diarrhea | 15 (17.4) | 12 (14.8) | 0.645 |
| Grade ≥ 3 adverse events | 39 (45.3) | 16 (19.8) | < 0.001 |
| General weakness | 30 (34.9) | 40 (49.4) | 0.058 |
| Dermatologic adverse event | 12 (14.0) | 34 (42.0) | < 0.001 |
G-CSF, granulocyte-colony stimulating factor; Gem + nabPTX: Gemcitabine plus nab-paclitaxel.